# The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

> **NCT04839380** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 49 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ruxolitinib cream

## Key facts

- **NCT ID:** NCT04839380
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2022-11-18
- **Final completion:** 2022-11-18
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839380, "The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04839380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*